SI2366396T1 - Slikanje miokardne perfuzije ob uporabi adenozinskih receptorskih agonistov - Google Patents

Slikanje miokardne perfuzije ob uporabi adenozinskih receptorskih agonistov

Info

Publication number
SI2366396T1
SI2366396T1 SI200432079T SI200432079T SI2366396T1 SI 2366396 T1 SI2366396 T1 SI 2366396T1 SI 200432079 T SI200432079 T SI 200432079T SI 200432079 T SI200432079 T SI 200432079T SI 2366396 T1 SI2366396 T1 SI 2366396T1
Authority
SI
Slovenia
Prior art keywords
receptor agonists
adenosine receptor
myocardial perfusion
perfusion imaging
imaging
Prior art date
Application number
SI200432079T
Other languages
English (en)
Inventor
Luiz Belardinelli
Mitchell Rosner
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI2366396T1 publication Critical patent/SI2366396T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200432079T 2004-01-27 2004-01-27 Slikanje miokardne perfuzije ob uporabi adenozinskih receptorskih agonistov SI2366396T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/002304 WO2005082379A1 (en) 2004-01-27 2004-01-27 Myocardial perfusion imaging using adenosine receptor agonists

Publications (1)

Publication Number Publication Date
SI2366396T1 true SI2366396T1 (sl) 2013-10-30

Family

ID=34912870

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432079T SI2366396T1 (sl) 2004-01-27 2004-01-27 Slikanje miokardne perfuzije ob uporabi adenozinskih receptorskih agonistov
SI200432077T SI1708721T1 (sl) 2004-01-27 2004-01-27 Slikanje miokardne perfuzije ob uporabi adenozinskih receptorskih agonistov

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200432077T SI1708721T1 (sl) 2004-01-27 2004-01-27 Slikanje miokardne perfuzije ob uporabi adenozinskih receptorskih agonistov

Country Status (16)

Country Link
EP (2) EP1708721B1 (sl)
JP (1) JP4818127B2 (sl)
KR (1) KR101143826B1 (sl)
CN (1) CN1905887A (sl)
AU (1) AU2004316372B2 (sl)
CA (2) CA2691611A1 (sl)
CY (2) CY1114928T1 (sl)
DK (2) DK1708721T3 (sl)
ES (2) ES2428843T3 (sl)
HK (1) HK1162139A1 (sl)
IL (1) IL177119A (sl)
NO (1) NO337132B1 (sl)
NZ (1) NZ548794A (sl)
PT (2) PT2366396E (sl)
SI (2) SI2366396T1 (sl)
WO (1) WO2005082379A1 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
RU2007114908A (ru) * 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
WO2009108829A2 (en) * 2008-02-29 2009-09-03 King Pharmaceuticals Research And Development, Inc. Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
RU2502461C1 (ru) * 2012-06-04 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РКНПК" Минздравсоцразвития России) Способ диагностики ишемии миокарда у больных кардиальным синдромом х
WO2018042363A1 (en) * 2016-09-01 2018-03-08 Leiutis Pharmaceuticals Pvt, Ltd. Pharmaceutical formulations of regadenoson

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method

Also Published As

Publication number Publication date
JP4818127B2 (ja) 2011-11-16
EP2366396B1 (en) 2013-08-07
CA2554169C (en) 2010-03-16
ES2428843T8 (es) 2013-12-26
AU2004316372A1 (en) 2005-09-09
CY1114928T1 (el) 2016-12-14
NO20063629L (no) 2006-10-26
WO2005082379A1 (en) 2005-09-09
NO337132B1 (no) 2016-01-25
IL177119A (en) 2011-07-31
ES2428843T3 (es) 2013-11-11
CA2691611A1 (en) 2005-09-09
WO2005082379A8 (en) 2006-01-19
PT1708721E (pt) 2013-10-02
JP2007519718A (ja) 2007-07-19
ES2426913T8 (es) 2013-12-16
HK1162139A1 (en) 2012-08-24
CN1905887A (zh) 2007-01-31
AU2004316372B2 (en) 2011-05-12
EP1708721A1 (en) 2006-10-11
KR101143826B1 (ko) 2012-05-11
CA2554169A1 (en) 2005-09-09
IL177119A0 (en) 2008-03-20
KR20060130630A (ko) 2006-12-19
CY1115926T1 (el) 2017-01-25
EP1708721B1 (en) 2013-08-07
DK2366396T3 (da) 2013-09-08
NZ548794A (en) 2009-07-31
EP2366396A1 (en) 2011-09-21
DK1708721T3 (da) 2013-09-08
PT2366396E (pt) 2013-10-03
ES2426913T3 (es) 2013-10-25
SI1708721T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
HK1162139A1 (en) Myocardial perfusion imaging using adenosine receptor agonists
IL243840A0 (en) Contrast agents for myocardial perfusion imaging
IL178911A0 (en) Contrast agents for myocardial perfusion imaging
IL166555A0 (en) Myocardial perfusion imaging a2a receptor agaonists
ZA200703229B (en) Use of A2A adenosine receptor agonists
IL188476A0 (en) Pyridazinone derivatives as thyroid hormone receptor agonists
IL194398A0 (en) Bisadenosine compounds as adenosine a2a receptor agonists
ZA200610571B (en) Selective serotonin receptor inverse agonists as therapeutics for disease
IL181716A0 (en) Purine derivatives as a3 and a1 adenosine receptor agonists
SG144146A1 (en) Adenosine receptor agonists
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
IL201234A0 (en) Adenosine a2a receptor antagonists
ZA200702843B (en) Compounds for myocardial perfusion imaging
IL174056A0 (en) Novel adenosine a3 receptor agonists
IL184532A0 (en) Novel adenosine a3 receptor modulators
ZA200609031B (en) Contrast agents for myocardial perfusion imaging
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
ZA200606223B (en) Myocardial persufion imaging using adenosine receptor agonists
ZA200500855B (en) Myocardial perfusion imaging using A2A receptor agonist
PL380999A1 (pl) Sposób obrazowania perfuzji mięśnia sercowego przy użyciu agonistów receptora adenozyny
IL177721A0 (en) Adenosine receptor agonists
SI1919878T1 (sl) Derivati piridazinona kot agonisti receptorja ĺ äśitniäśnega hormona
GB0505786D0 (en) A2b adenosine receptor antagonists
ZA200702635B (en) Purine derivatives for use as adenosin A-2A receptor agonists
GB0516439D0 (en) EP2 receptor agonists